<DOC>
	<DOCNO>NCT00003934</DOCNO>
	<brief_summary>This randomized phase III trial study tretinoin combination chemotherapy see well work compare tretinoin , combination chemotherapy , arsenic trioxide treat patient acute promyelocytic leukemia treat previously . Drugs use chemotherapy , daunorubicin , cytarabine , mercaptopurine , methotrexate , arsenic trioxide , work different way stop cancer cell divide stop grow die . Tretinoin may help leukemia cell develop normal white blood cell . It yet know regimen effective acute promyelocytic leukemia .</brief_summary>
	<brief_title>Tretinoin , Cytarabine , Daunorubicin Hydrochloride With Without Arsenic Trioxide Followed Tretinoin With Without Mercaptopurine Methotrexate Treating Patients With Acute Promyelocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : . To compare efficacy ( event-free survival ) toxicities two induction/consolidation therapy patient untreated APL : ATRA/ara-C/daunorubicin without arsenic trioxide ( As2O3 ) . II . To evaluate efficacy ( disease-free survival ) toxicities maintenance therapy intermittent ATRA v intermittent ATRA plus 6-MP/MTX patient APL achieve complete response . III . To explore relationship CD56 expression diagnosis clinical outcome . IV . To evaluate cardiac toxicity intensive daunorubicin therapy , give study , pediatric patient . OUTLINE : This randomize , multicenter study . Patients stratify accord age ( 15 vs 15 60 v 60 ) induction phase . Patients stratify accord age , induction phase , consolidation arm ( v without arsenic trioxide ) consolidation phase . Patients age 5 receive arsenic trioxide . Induction : All patient receive oral tretinoin every 12 hour begin day 1 complete response maximum 90 day . Patients also receive daunorubicin IV day 3-6 cytarabine IV continuously day 3-9 . Consolidation : All patient achieve complete response ( CR ) , partial response ( PR ) completion tretinoin , proceed consolidation within 2 week achieve CR PR , prior 30 day start induction . Patients randomize 1 2 treatment arm . Arm I : Patients receive oral tretinoin every 12 hour day 1-7 daunorubicin IV day 1-2 day 1-3 , depend age . Patients may receive additional course . Treatment begin early 2 week later 4 week hematopoietic recovery . Arm II : Patients receive arsenic trioxide IV 2 hour daily 5 day week 5 week . After 2-week rest , patient receive second course arsenic trioxide . Patients receive tretinoin daunorubicin arm I . Maintenance : Patients maintain CR PR consolidation therapy proceed maintenance therapy , begin earlier 2 week later 4 week hematopoietic recovery . Patients randomize 1 2 treatment arm . Arm I : Patients receive oral tretinoin every 12 hour 7 day every week 1 year . Arm II : Patients receive oral tretinoin arm I . Patients also receive oral mercaptopurine day oral methotrexate weekly 1 year . Maintenance therapy continue 1 year absence unacceptable toxicity . Patients follow every 2 month 2 year , every 3 month 1 year , every 6 month 2 year , annually 5 year . PROJECTED ACCRUAL : A total 522 patient ( 456 adult 66 pediatric ) accrue study within 4.75 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Patients must clinical diagnosis acute promyelocytic leukemia ( APL ) proof APL morphology ( FABM3 ) confirm RTPCR assay ; patient may enter prior completion RTPCR study , patient subsequently find PMLRARα negative RARαPML negative remove protocol treatment FAB clasification : aspirate smear must show M3 characteristic least 30 % cell must abnormal promyelocytes heavy granulation ; overall marrow cellularity must normocellular hypercellular ; patient microgranular variant ( M3V ) eligible , diagnosis base characteristic morphologic finding ( e.g. , reniform bilobed nuclei ) RTPCR assay : submission sample RTPCR assay PMLRARα/RARαPML transcript mandatory ; result know prior initiation therapy ; assay subsequently find negative , patient remove protocol treatment treat discretion responsible physician Prior treatment : patient must receive systemic definitive treatment APL , include cytotoxic chemotherapy retinoids ; prior therapy corticosteroid , hydroxyurea leukapheresis exclude patient Nonpregnant , nonnursing : treatment protocol would expose unborn child significant risk ; patient pregnant plan become pregnant treatment ; woman men reproductive potential agree use effective mean birth control ; extremely high risk fetal malformation pregnancy occur ATRA amount even short period</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>